Physician profile
Brian P Mitu
NPI 1528015849
$4,124.00
in general payments reported to CMS, 2019-2025
29 companies · $1,124 in 2025
The $1,124 reported for 2025 was more than what 89% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,343 · 2022: $386 · 2023: $534 · 2024: $738 · 2025: $1,124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,395.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $918.47 | 2021-2024 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $529.24 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $400.88 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $289.75 | 2021-2025 | Invega Sustenna |
| Glaxosmithkline, LLC. | $263.16 | 2021-2024 | Arexvy, Trelegy Ellipta |
| Alkermes, INC. | $246.52 | 2025 | Lybalvi, Aristada, Aristada Initio |
| Amgen INC. | $219.26 | 2021-2024 | Repatha |
| Pfizer INC. | $175.84 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $145.00 | 2021-2025 | Cobenfy |
| Merck Sharp & Dohme LLC | $118.48 | 2021-2025 | Capvaxive, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.84 | 2021-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.31 | 2021-2022 | |
| Amarin Pharma, INC. | $86.23 | 2021 | |
| Abbvie INC. | $83.71 | 2021-2024 | |
| Exact Sciences Corporation | $67.28 | 2025 | Cologuard Collection Kit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $65.94 | 2021-2025 | Zepbound, Mounjaro |
| Esperion Therapeutics, INC. | $51.31 | 2021 | |
| Novartis Pharmaceuticals Corporation | $38.62 | 2021 | |
| Dexcom, INC. | $31.46 | 2024 | Dexcom G6 Transmitter |
| Lundbeck LLC | $27.27 | 2025 | Vyepti |
| Hologic Sales and Service, LLC | $24.18 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $22.00 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.61 | 2025 | Caplyta |
| Intra-Sana Laboratories | $20.97 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Masimo Corporation | $20.46 | 2024 | Bridge |
| Viiv Healthcare Company | $18.21 | 2022 | |
| Abbott Laboratories | $17.57 | 2025 | Eterna |
| Medtronic, INC. | $15.57 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $11.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Mitu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.